Research programme: diabetes therapy - Arisaph Pharmaceuticals
Alternative Names: ARI-2406; ARI-2651Latest Information Update: 04 Nov 2017
At a glance
- Originator Arisaph Pharmaceuticals
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Glucagon-like peptide 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 13 Oct 2015 Preclinical development is ongoing in the USA
- 26 Jun 2008 This programme is still in active development